Lantheus Sued by Novartis for Patent Infringement on Lutathera

Lantheus was sued by Novartis entities for patent infringement in response to the company’s filing of a Abbreviated New Drug Application for a generic version of lutathera.

• Company believes it is the “first applicant” to have filed a substantially complete ANDA containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act
• Company believes it is eligible for 180 days of generic marketing exclusivity in the US
• Novartis has filed a lawsuit for patent infringement in the District Court for the District of Delaware

To view the source of this information, click here

To contact the reporter on this ...